Please upgrade your browser.
Renal cell carcinoma accounts for approximately 3% of all human malignancies. The use of cytokines in metastatic stage of disease has been the standard until last decades, presenting partial and short duration responses. Research on angiogenesis in renal carcinoma has brought important advances to understand tumor biology and to allow us development of new antiangiogenic drugs.
IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
OCL 500 is a microspherical agent in development for the treatment of highly vascularised tumours, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids.
This report summarizes the U.S. Food and Drug Administration (FDA)'s approval of temsirolimus (Torisel®), on May 30, 2007, for the treatment of advanced renal cell carcinoma (RCC). Information provided includes regulatory history, study design, study results, and literature review.
Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent
In the present study, the activity and protein and mRNA expression of these glycoproteins were analysed in a subset of clear-cell (CCRCC) and chromophobe (ChRCC) renal cell carcinomas, and in renal oncocytomas (RO).
Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes that mediate cell survival, proliferation, and angiogenesis and is aberrantly activated in various types of malignancies, including renal cell carcinoma (RCC). We examined whether it could be a novel therapeutic target for RCC by using the STAT3 inhibitor WP1066.
CO2 angiography not only helps prevent undesired complications, but it can also assist in the performance of interventional oncologic procedures
Patients aged 75 years or older who have confined kidney tumors do not live longer if they have their entire kidney removed.
Sunitinib is approved for treatment of advanced renal cell carcinoma (rcc). Based on a clinical observation that patients receiving sunitinib developed macrocytosis, we undertook a study to further define this observation.
Joe Sheetz passed away in August 2006 at the age of 60 after a lengthy battle with kidney cancer. He was executive vice president of store development for 25 years. He was succeed by his son, Joe S. Sheetz.
If ridaforolimus is brought to market it would likely compete with Novartis oral mTOR inhibitor Afinitor, which was approved by the FDA last April.
|Powered by NeonCRM|